*|MC:SUBJECT|*
BioRN News December 2022
View this email in your browser

Dear *|FNAME|* *|LNAME|*,


with the pandemic slowing down and everybody looking carefully to a "back to normal" scenario, we all rushed to recover the time lost to reconnect with old and new partners. Overwhelmed by conferences, fairs and networking events, the 2022 is coming to an end.

On November 29, we had our last Lounge with Katja Schenke-Layland from NMI Natural and Medical Sciences Institute at the University of Tübingen [more] and last BioRN Espresso from our annual series on SAMPLES and DATA to improve healthcare: Value, Potential, Challenges [more].

Finally, members of BioRN Network met for the annual general assembly, a celebrative occasion to summarize major achievements and plan new assignments. BioRN is closing this year with a total of 143 institutional members. Success and growth were proofed with the presentation of the results from several projects BioRN has launched or supported. Start-Ups will be invited to the network with a special reduced member fee [more].

Before sledding into holidays here few numbers extracted from our Annual Report 2022:
  • 143 members (20 new members in 2022)
  • BioRN is Founding Partner of BioLabs Heidelberg
  • BioRN secures the GOLD label for cluster excellence (2022-2023)
  • Newly established Data Exchange Think Tank
  • New Horizon Europe funded project: INNAXE
  • Kick off of the new service BiointeRNational
  • 1 BioRN Annual Conference, 2 Investors' days, 8 BioRN Lounges, 3 BioRN Espresso, 3 BioRN Saloon (aka 'Stammtisch'), 2 Workshops for and by members, 2 Foreign Delegations, 1 Dragon Boat Cup with two teams
  • and [more] in our report
Happy Holiday!
 
Annalisa Zuccotti
Events & Communication Lead
BioRN Life Science Cluster Rhine-Neckar
01 | Research Highlights & News
02 | New Members
03 | Events Spotlight
04 | Event Calendar & Discounts
05 | Open Positions
01| Research Highlights & News

Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept [more]

Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism [more]

DKFZ: Epigenetic emergency switch improves defense against infections [more]

DKFZ & UKHD: How brain tumors keep the beat - and why that makes them so dangerous [more]

New drug for metastatic prostate cancer developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University now also approved in Europe [more]

EMBL: Genomic Data Infrastructure – integrating genomics into healthcare [more]

European Vaccine Initiative: Protecting the next generations with vaccines [more]

Heidelberg University: Ioannis Sarropoulos receives Birnstiel Award for his research on non-coding genomic sequences in mammals  [more]

Heidelberg / Mannheim University Hospital Link-Up: Reviewed and Rapid Implementation Recommended  [more]

KiTZ, DKFZ, UKHD: Leibniz Prize for Stefan Pfister  [more]

Novaliq: Sonja Kroesser named Top 25 Women Leaders in Biotechnology of 2022  [more]

Innovation challenges and awards:
  • Merck KGaA Darmstadt Germany Innovation Cup 2023 [more]
  • Apply for Sanofi iDEA-iTECH Awards [more] 
  • Apply until 20. January 2023 to the 4C Accelerator Tübingen #5! [more]

02 | New Members


The Cultivated B. (TCB) is breaking new ground in the development of advanced biotechnology and bioengineering to enhance access to plant and cell-based alternative protein sources. By providing pioneering technology, TCB enriches the alternative protein and agritech industries and enables other companies to produce alternative proteins at an industrial scale.

GenCC GmbH is focusing on utilizing the popular genome-editing tool CRISPR/Cas for cancer therapy. Due to the major advances in gene editing (e.g. CRISPR / Cas 9), and molecular tumor profiling of different types of cancer in recent years, personalized cancer therapy is increasingly becoming the focus of attention in cancer research.

Docuply offer a GxP document management and collaboration platform for pharmaceutical and biotech companies that enables seamless collaboration with third parties. Docuply enables pharmaceutical and biotech companies to run smooth and GxP-compliant day-to-day operations with third parties and distributed teams.

03 | Events Spotlight

04 | Event Calendar & Discounts


Online-Symposium "Personalisierte Medizin für maßgeschneiderte Krebstherapien - Brustkrebs"
January 12, 2023 - Online >>
 

eHealth Symposium Südwest 2023
January 25, 2023 - Kaiserslautern >>
 

Einschnitte – Einblicke: Digitalisierung | Fusion | KI in der Chirurgie
January 25, 2023 - Online >>
 
Good Things Come in Small Packages: Purifying miRNA from Plasma, Serum and Exosomes
January 25, 2023 - Online >>
 
German Pavilion @ BIO Convention
Join the German Pavillon in the exhibition hall at reduced fees.
Application Deadline: January 31, 2023
June 5-8, 2023 - Boston, USA >>

 

05 | Open Positions


Apogenix: Manager Quality Assurance / Quality Management (m/w/d) [more]

BioMed X:
Postdoctoral Position (all genders) in Materials Science – Group Biomarker Detection in Brain (BDB)  [more]

KIT Innovation gGmbH: Startup Accelerator Lead (m/w/d) Artificial Intelligence [more]

Sciomics GmbH:
  • Wissenschaftliches Sales & Marketing (m/w/d) [more]
  • Research Asscociate oder Erfahrene(r) BTA / Biologielaborant / MTA (m/w/d) [more]
  • BTA / Biologielaborant / MTA (m/w/d) [more]

Universitätsklinikum Heidelberg: Clinical Scientist / Medical Doctor (m/f/d) [more]
 
We have partnered with ProcEurope!
What are the benefits for BioRN Members?
  • Significant discounts with Fisher Scientific, an average 44% off list price as well as no delivery, dry ice, hazardous or minimum order charges. 
  • New Suppliers reviewed and brought on board on a regular bases. 
  • No change to processes! ProcEurope negotiate the pricing, but the ordering method stays the same, you order directly with the supplier and liaise with the same sales representative as before.
  • No need to pay ProcEurope's €250 annual fee.

Find out more >>                                                                                      Download
Tweet
Forward
Share

Imprint


Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

Responsible for the content:
Dr. Julia Schaft

Editor: Dr. Annalisa Zuccotti

Our mailing address is:
*|HTML:LIST_ADDRESS_HTML|* *|END:IF|*

Commercial Register: Mannheim, HRB 704801
VAT ID: DE 2630 64 014

unsubscribe from this list    update subscription preferences 

*|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*